At our institution, both TOP2A overexpression and TOP2A amplified had been consecutively evaluated using immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH) in patients with breast cancer between May 2005 and April 2015. Here, TOP2A is linked to breast carcinoma.